Genetic polymorphism of the plasminogen activator inhibitor‐1 is associated with an increased risk of endometrial cancer

来自 EBSCO

阅读量：

作者：

CK Su，KT Yeh，CB Yeh，PH Wang，SC Ho，MC Chou，KC Liu，SF Yang，YC Yi

展开

摘要：

Background and ObjectivesTo investigate the association of uPA system genes, including uPA, uPA receptor (uPAR), and plasminogen activator inhibitor (PAI)-1 gene polymorphisms, with risk of endometrial cancer.MethodsIn the present case control study, we enrolled a total of 134 patients with endometrial cancer confirmed by histopathology and 302 unrelated healthy individuals. Genetic polymorphisms of uPA system genes, including uPA rs4065 C/T SNP, uPAR rs344781 T/C SNP, and PAI-1 rs1799889 4G/5G SNP were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) genotyping analysis.ResultsFrequency of PAI-1 rs1799889 4G/4G genotype and 4G allele differed significantly between patients with endometrial cancer (36.6% and 61.6%, respectively) and healthy individuals (25.5% and 52.2%, respectively). Individuals with PAI-1 rs1799889 4G/4G genotype were at higher risk of endometrial cancer (OR=2.26; 95% CI: 1.20–4.27). Stratification analysis showed individuals with PAI-1 rs1799889 4G/4G genotype were at elevated risk for endometrioid type (OR=2.49; 95% CI 1.27–4.88), low stage (stages I–II) endometrial cancer (OR=2.34; 95% CI 1.21–4.52). However, no significant differences in uPA C/T SNP, uPAR T/C SNP genotypes were observed between endometrial carcinoma cases and controls.ConclusionsIndividuals with PAI-1 rs1799889 4G/4G genotype were at significantly higher risk of endometrial cancer in this study. J. Surg. Oncol. 2011; 104:755–759. 2011 Wiley Periodicals, Inc.

展开

关键词：

endometrial cancer polymorphism urokinase plasminogen activator plasminogen activator inhibitor

DOI：

10.1002/jso.22035

被引量：

年份：

2011